Amir Bar‐Shai

Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study

Andrew Menzies‐Gow, Michael E. Wechsler, Christopher E. Brightling et al. · The Lancet Respiratory Medicine · 2023 · 127 citations · Full text

Asthma, Rheumatology, Allergy +9

H1N1 Influenza: Initial Chest Radiographic Findings in Helping Predict Patient Outcome

Galit Aviram, Amir Bar‐Shai, Jacob Sosna et al. · Radiology · 2010 · 102 citations

NLRP3 inflammasome activity is upregulated in an in-vitro model of COPD exacerbation

Noy Nachmias, Sheila Langier, Rafael Y. Brzezinski et al. · PLoS ONE · 2019 · 55 citations · Full text

p53 in Bronchial Club Cells Facilitates Chronic Lung Inflammation by Promoting Senescence

Adi Sagiv, Amir Bar‐Shai, Naama Levi et al. · Cell Reports · 2018 · 52 citations · Full text

Inflammation, Inflammatory Lung Disease, Lung Inflammation +15

Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial

Dave Singh, Christopher E. Brightling, Klaus F. Rabe et al. · The Lancet Respiratory Medicine · 2024 · 48 citations · Full text

Advanced Lung Disease, Clinical Trials, Tezepelumab Versus Placebo +4